Axonics® to Report 2019 Second Quarter and Six-Month Financial Results and Host a Conference Call on August 5

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the second quarter and first six months of 2019, and provide an update on operations and FDA regulatory status after the market closes on Monday, August 5, 2019.

In conjunction with the release, the Company will host a conference call with the investment community that same day at 4:30 p.m. Eastern Time to discuss the financial results and current business developments.

Interested parties may access the live call via telephone by dialing (866) 687-5771 (U.S.) or (409) 217-8725 (International) and using passcode 6687965.

A live webcast of the call may be accessed by visiting the Events & Presentations page of the investors section of the Company’s website at ir.axonicsmodulation.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website for 90 days.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics System is the first rechargeable sacral neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain full-body MRI conditional labeling in Europe. Premarket approval for the System is currently pending with the U.S. FDA. For more information, visit the Company’s website at www.axonicsmodulation.com.

Contacts

Axonics’ Contact

Axonics Modulation Technologies, Inc.

Dan Dearen, +1-949-396-6320

President & Chief Financial Officer

ir@axonics.com

Investor & Media Contact

W2Opure

Matt Clawson, +1-949-370-8500

mclawson@w2ogroup.com

Staff

Recent Posts

Medical Imaging Equipment Market Size to Hit USD 62.51 Billion by 2031 with 4.5% CAGR | Business Market Insights

NEW YORK, June 20, 2025 /PRNewswire/ -- Players such as GE HealthCare, Siemens Healthineers, Philips,…

34 minutes ago

DIGITAL HEALTH LEADER JMIR PUBLICATIONS ANNOUNCES ITS 2025 IMPACT FACTOR RESULTS

The JMIR Publications portfolio of journals now includes 21 journals with a Journal Impact Factor, with…

34 minutes ago

Integrated Theranostics Solutions and Bridge Oncology Launch Turnkey Theranostics Program to Help Fast-Track Radioligand Therapy Adoption

PADUCAH, Ky., June 20, 2025 /PRNewswire/ -- Integrated Theranostics Solutions (ITS) and Bridge Oncology today…

34 minutes ago

Yale School of Medicine Launches Yale Biomedical Imaging Institute

NEW HAVEN, Conn., June 20, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) announces the launch of…

35 minutes ago

AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025…

35 minutes ago